AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytochrome P450 4F12

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9HCS2

UPID:

CP4FC_HUMAN

Alternative names:

CYPIVF12

Alternative UPACC:

Q9HCS2; E7ET51; O60389; Q5JPJ7; Q9HCS1

Background:

Cytochrome P450 4F12 (CYPIVF12) is a pivotal enzyme in the metabolism of polyunsaturated fatty acids (PUFAs) and xenobiotics. It catalyzes the hydroxylation of carbon hydrogen bonds, with a preference for the omega-2 position, and is involved in the metabolism of the antihistamine drug ebastine. This enzyme plays a crucial role in converting arachidonate to 18-hydroxy arachidonate and in the epoxidation of PUFAs such as docosapentaenoic and docosahexaenoic acids.

Therapeutic significance:

Understanding the role of Cytochrome P450 4F12 could open doors to potential therapeutic strategies, particularly in the modulation of PUFA metabolism and the detoxification of xenobiotics.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.